<DOC>
	<DOCNO>NCT00440583</DOCNO>
	<brief_summary>The purpose study determine effective Yt90-Zevalin therapy patient diffuse large B-cell lymphoma achieve least unconfirmed partial remission 6 cycle CHOP therapy .</brief_summary>
	<brief_title>The Response Study Yt90-Zevalin Patients With Diffuse Large B-cell Lymphoma After 6 Cycles CHOP</brief_title>
	<detailed_description>Diffuse large B-cell lymphoma ( DLBCL ) common lymphoid neoplasm account 30 % 40 % adult non-Hodgkin lymphoma ( NHL ) . DLCBL potentially curable disease . The ultimate goal introduce new modality treatment monoclonal antibody ( Ab ) -targeted therapy increase complete remission ( CR ) rate prolong event-free survival overall survival.In phase II trial , show DLBL addition rituximab CHOP feasible , increase ORR , include CR increase OS PFS patient DLBL.2 The benefit R-CHOP consistent across subgroup patient test , include good poor risk accord IPI independent young 70 year old 70 year age . Recently , new radiolabeled monoclonal antibody establish therapy malignant lymphoma induce high remission rate . Radiolabeled antibody particularly effective lymphoma cell highly sensitive radiation . In addition , local emission radiolabeled antibody able destroy cell close proximity bound antibody ( bystander effect ) therefore circumvent problem limit perfusion bulky poorly vascularize tumors.Ibritumomab covalently link tiuxetan chelate radiolabeled Yt90 , produce Yt90-ibritumomab tiuxetan ( Yt90-Zevalin ) . To optimize biodistribution , Rituximab give prior radiolabeled antibody . Yt90-ibritumomab-tiuxetan-treatment compare standard course Rituximab . ORR Yt90-ibritumomab tiuxetan group significantly high ORR Rituximab group ( 80 % vs. 56 % accord International Workshop Response criteria 73 % vs. 47 % accord protocol-defined evaluation response ) . Since radioimmunotherapy represent significant advance unlabeled immunotherapy treatment patient B-cell non-Hodgkin 's lymphoma , worthwhile study consolidation therapy Yt90-ibritumomab tiuxetan ( Yt90-Zevalin ) patient achieve least unconfirmed partial remission 6 cycle CHOP therapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm , CD 20 positive diffuse large Bcell lymphoma , meet 1 follow stage criterion : Bulky stage II disease , Stage III disease , Stage IV disease initial diagnosis . Bidimensionally measurable disease Age 18 75 Years Performance status Zubrod 02 Less 20,000/mcL circulate lymphoid cell WBC differential count Adequate section AND paraffin block OR ≥ 10 unstained section original diagnostic specimen available Needle aspiration cytology consider adequate No clinical evidence CNS involvement lymphoma No prior diagnosis indolent lymphoma No histologic transformation Life expectancy : Not specify Hepatic : Not specify Renal : Not specify Cardiovascular Ejection fraction ≥ 45 % MUGA OR No significant abnormality echocardiogram Pulmonary : No requirement continuous supplemental oxygen Other All adult patient reproductive potential must use contraception 6 month completion study treatment No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , stage I II cancer complete remission , carcinoma situ cervix No known HIV positive Written inform consent PRIOR CONCURRENT THERAPY : Biologic therapy : No prior antibody therapy lymphoma Chemotherapy : 6 cycle CHOP Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy lymphoma Surgery : No prior solid organ transplantation Previous antineoplastic treatment 6 cycle CHOP initial treatment DLBCL Positive HIV serology Positive serology HCV presence HCV RNA chronic hepatitis Positive serology HBV presence HBV RNA chronic hepatitis Serum creatinine bilirubin &gt; 2.5 x upper limit normal Active uncontrolled infection Concurrent severe and/or uncontrolled medical disease could compromise participation study Patients 25 % bone marrow infiltrate lymphoma cell Patients platelet count &lt; 100,000/µl neutrophil count &lt; 1500/µl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>CHOP-Z</keyword>
</DOC>